171 related articles for article (PubMed ID: 1369672)
1. Discriminative stimulus properties of hallucinogens and related designer drugs.
Glennon RA
NIDA Res Monogr; 1991; (116):25-44. PubMed ID: 1369672
[TBL] [Abstract][Full Text] [Related]
2. Hallucinogens and serotonergic mechanisms.
Glennon RA; Teitler M; Sanders-Bush E
NIDA Res Monogr; 1992; 119():131-5. PubMed ID: 1435968
[TBL] [Abstract][Full Text] [Related]
3. Phenylalkylamine stimulants, hallucinogens, and designer drugs.
Glennon RA
NIDA Res Monogr; 1990; 105():154-60. PubMed ID: 1678860
[TBL] [Abstract][Full Text] [Related]
4. Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships.
Glennon RA
NIDA Res Monogr; 1989; 94():43-67. PubMed ID: 2575229
[No Abstract] [Full Text] [Related]
5. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
Callahan PM; Appel JB
J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
[TBL] [Abstract][Full Text] [Related]
6. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo.
Johanson CE; Kilbey M; Gatchalian K; Tancer M
Drug Alcohol Depend; 2006 Jan; 81(1):27-36. PubMed ID: 15975736
[TBL] [Abstract][Full Text] [Related]
7. Do classical hallucinogens act as 5-HT2 agonists or antagonists?
Glennon RA
Neuropsychopharmacology; 1990; 3(5-6):509-17. PubMed ID: 2078284
[TBL] [Abstract][Full Text] [Related]
8. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action.
Marona-Lewicka D; Nichols DE
Pharmacol Biochem Behav; 2007 Oct; 87(4):453-61. PubMed ID: 17618679
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
Rosenzweig-Lipson S; Bergman J
J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of nicotine discrimination and discriminative stimulus effects of nicotine in rats chronically exposed to caffeine.
Gasior M; Shoaib M; Yasar S; Jaszyna M; Goldberg SR
J Pharmacol Exp Ther; 1999 Mar; 288(3):1053-73. PubMed ID: 10027843
[TBL] [Abstract][Full Text] [Related]
11. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
[TBL] [Abstract][Full Text] [Related]
12. Clinical toxicology of newer recreational drugs.
Hill SL; Thomas SH
Clin Toxicol (Phila); 2011 Oct; 49(8):705-19. PubMed ID: 21970769
[TBL] [Abstract][Full Text] [Related]
13. Discriminative stimulus properties of clenbuterol: evidence for beta adrenergic involvement.
McElroy JF; O'Donnell JM
J Pharmacol Exp Ther; 1988 Apr; 245(1):155-63. PubMed ID: 2834535
[TBL] [Abstract][Full Text] [Related]
14. Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 1.25 mg/kg clozapine vs. 5.0 mg/kg clozapine vs. vehicle.
Prus AJ; Philibin SD; Pehrson AL; Porter JH
Behav Pharmacol; 2006 Mar; 17(2):185-94. PubMed ID: 16495726
[TBL] [Abstract][Full Text] [Related]
15. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity.
Oberlender R; Nichols DE
J Pharmacol Exp Ther; 1990 Dec; 255(3):1098-106. PubMed ID: 1979813
[TBL] [Abstract][Full Text] [Related]
16. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships and mechanism of action of hallucinogenic agents based on drug discrimination and radioligand binding studies.
Glennon RA; Titeler M; Young R
Psychopharmacol Bull; 1986; 22(3):953-8. PubMed ID: 3025916
[No Abstract] [Full Text] [Related]
18. Arylalkylamine drugs of abuse: an overview of drug discrimination studies.
Glennon RA
Pharmacol Biochem Behav; 1999 Oct; 64(2):251-6. PubMed ID: 10515299
[TBL] [Abstract][Full Text] [Related]
19. Further characterization of the stimulus properties of 5,6,7,8-tetrahydro-1,3-dioxolo[4,5-g]isoquinoline.
Glennon RA; Young R; Rangisetty JB
Pharmacol Biochem Behav; 2002 May; 72(1-2):379-87. PubMed ID: 11900809
[TBL] [Abstract][Full Text] [Related]
20. Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine.
Corazza O; Schifano F; Simonato P; Fergus S; Assi S; Stair J; Corkery J; Trincas G; Deluca P; Davey Z; Blaszko U; Demetrovics Z; Moskalewicz J; Enea A; di Melchiorre G; Mervo B; di Furia L; Farre M; Flesland L; Pasinetti M; Pezzolesi C; Pisarska A; Shapiro H; Siemann H; Skutle A; Enea A; di Melchiorre G; Sferrazza E; Torrens M; van der Kreeft P; Zummo D; Scherbaum N
Hum Psychopharmacol; 2012 Mar; 27(2):145-9. PubMed ID: 22389078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
